Moneycontrol PRO
Upcoming Event : LeapToUnicorn - mentoring, networking and fundraising for startups. Register now
you are here: HomeNewsBusiness

ADB, Wabag Sign Rs 200 crore debt facility to support sanitation and water security in India

The board of Va Tech Wabag approved the proposal for fundraising by way of issuance of non-convertible debentures up to Rs 200 crore to ADB on a private placement basis.

November 25, 2022 / 07:15 PM IST
(Representational image)

(Representational image)

The Asian Development Bank (ADB) has signed a $25 million or Rs 200 crore debt facility with VA Tech Wabag to support sanitation and water security through the development of new sewage treatment plants in India.

The board of Va Tech Wabag approved the proposal for fundraising by way of issuance of non-convertible debentures (NCDs) up to Rs 200 crore to ADB on a private placement basis.

The issue could be done in one or more tranches/series, subject to necessary approvals, permissions, consents and sanctions as may be required. The tenure of the debentures is 5 years and 3 months.

This will be ADB’s first investment in a Water sector company in India and it will also provide technical assistance of up to $35,000 to enhance Wabag’s capacity to assess and mitigate environmental and social risks for future projects.

“The disposal of wastewater without proper treatment has put significant pressure on India’s already scarce water resources and the quality of those resources,” said ADB’s Private Sector Operations Department Director General Suzanne Gaboury.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Further, the board has also approved the appointment of Integrated Registry Management Services as the registrar and transfer agent (RTA) with immediate effect for issuance/allotment of the above-said NCD to the ADB.
Moneycontrol News